We recently updated our Privacy Notice and Terms of Use.
Med-IQ
Advances in the Management of Brain Metastases
Webcast Webcast

Advances in the Management of Brain Metastases



This activity was developed by Med-IQ in collaboration with Duke Health.

Med-IQ       Duke Medicine

Released:
10/11/18
Expires:
10/10/19
PDF:

Maximum Credits:

0.5
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Webcast Webcast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
10/11/18

Expires:
10/10/19

PDF:

Maximum Credits:
0.5
Webcast Webcast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
10/11/18
Expires:
10/10/19
PDF:


Maximum Credits:
0.5


Overview: In this 30-minute webcast, expert faculty review recent advances in the management of brain malignancies. In particular, April K.S. Salama, MD, discusses the current understanding of systemic therapy, John Kirkpatrick, MD, PhD, discusses advances in radiation therapy, and Peter Fecci, MD, PhD, discusses surgical improvements for brain metastasis.

CME Information:

Faculty
Peter E. Fecci, MD, PhD
Assistant Professor of Neurosurgery
Duke University School of Medicine
Director, Duke Brain Tumor Immunotherapy Program
Co-Director, Duke Center for Brain and Spine Metastasis
Associate Deputy Director, Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Durham, NC

John Kirkpatrick, MD, PhD
Professor and Clinical Director of Radiation Oncology
Professor of Neurosurgery
Duke University School of Medicine
Duke Cancer Institute
Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
Co-Director, Duke Center for Brain and Spine Metastasis
Durham, NC

April K.S. Salama, MD
Associate Professor of Medicine
Duke University School of Medicine
Director, Melanoma Program
Duke Cancer Institute
Durham, NC
 
Activity Planners
Iwona Misiuta, PhD, MHA
Clinical Content Manager
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI
 
Learning Objectives
Upon completion, participants should be able to:

  • Understand advances in systemic therapy that can impact the management of brain metastases
  • Describe the key differences in rates of recurrence and cognitive decline associated with stereotactic radiosurgery versus whole-brain radiation therapy in patients with brain metastases
  • Describe the current uses and limitations of laser interstitial thermal therapy for intracranial metastatic disease

Target Audience
This activity is intended for oncologists and hematologists.

Statement of Need
Estimates show that up to 14% of individuals with cancer in the United States will develop brain metastases. Treating brain metastases remains challenging for oncologists and hematologists; indeed, the survival rate for the majority of patients is less than 1 year. Currently, the mainstay of treatment consists of stereotactic radiosurgery, surgical resection, whole-brain radiation therapy, or a combination of these modalities. Clinicians must be familiar with recent advances in these therapies to provide optimal care for patients with brain metastases.

Collaboration Statement
This activity was developed by Med-IQ in collaboration with Duke Health.

Med-IQ      Duke Medicine

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
 
Instructions to Receive Credit
To receive credit, read the introductory CME material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: October 11, 2018
Expiration Date: October 10, 2019
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Peter E. Fecci, MD, PhD
Consulting fees/advisory boards: Eisai Inc., Monteris Medical
 
John Kirkpatrick, MD, PhD
Ownership interest (stocks/stock options – excluding mutual funds): ClearSight RT Products, LLC
 
April K.S. Salama, MD
Consulting fees/advisory boards/speaker: Biocryst Pharmaceuticals, Inc., Bristol-Myers Squibb, Merck & Co., Inc.
Principal investigator: Bristol-Myers Squibb, Celldex Therapeutics, Dynavax Technologies Corporation, Genentech, Immunocore, Merck & Co., Inc., Reata Pharmaceuticals, Inc.
Other (spouse-principal investigator): AbbVie Inc.

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information 
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Copyright
© 2018 Med-IQ, Inc. and Duke University Health System
 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.